Categories

Tag: Jessica DaMassa

#Healthin2Point00, Episode 210 | Babylon acquires Meritage IPA, Ro acquires Modern Fertility & more

This week on Health in 2 Point 00, we’ve got big money, acquisitions, CVS Health starting its own decentralized clinical trials business, AND we’ve got Morgan Health. On Episode 210, Jess asks me about Babylon buying Meritage IPA, looking to add their digital front end to this doctors’ network, and Ro acquiring Modern Fertility for $225 million. Next, telehealth company Wheel gets $50 million in a Series B and digital pathology startup PathAI gets $165 million. Finally, SymphonyRM gets $25 million in a Series B. —Matthew Holt

#Healthin2Point00, Episode 209 | Funding for Lyra, DrFirst, Jasper Health & Cue Health

Today on Health in 2 Point 00, we catch Jess on the road again! On Episode 209, Jess is shocked at Lyra’s $200 million raise, bringing their total to a whopping $675 million – and their valuation is somewhere in the $4 billion range. What does this mean for the mental health space? Next, DrFirst gets $50 million. They were doing e-prescribing back in the day, what are they up to now? Jasper Health raises $6.75 million for a new play in cancer navigation. Finally testing company Cue Health raises $235 million, bringing their total to $405 million, plus they’ve got some really big federal grants. —Matthew Holt

Komodo Health’s CEO on $220M Series E & What’s REALLY Happening with Big Data in Healthcare

By JESSICA DaMASSA, WTF HEALTH

You know all that “magic” that machine learning is meant to bring to seemingly lackluster healthcare data and our limited understanding of it? Komodo Health’s co-founder & CEO Arif Nathoo demystifies the wizardry of one of our favorite buzz phrases, “The Algorithm,” and gives us a colorful overview of how his startup is making data useful to the way payers, health systems, and pharma co’s study populations at-scale. Komodo’s raised $314M to-date, closing a MASSIVE $220M Series E backed by Tiger Global Management, Casdin Capital, ICONIQ Growth, Andreessen Horowitz, and SVB Capital in April, and after hearing this enthusiastic explanation of what they’re working on – and the market potential for it – we understand why.

At its most simplistic, Komodo is using de-identified healthcare claims data as a base from which to learn how patients flow through the healthcare system. Other data sets are brought in and layered onto that “patient-flow, dollar-flow” claims trail in effort create a new vantage point for seeing what’s happening within the system, at a population level. That insight can then be used to predict patient behavior and provide evidenced analysis for how the system can be improved. Don’t worry: Arif provides lots of detailed examples and talks through exactly what kind of data can (and currently can’t) be pulled into the mix. If you want to get smart on the “Big Data” opportunity in healthcare and how it’s going to be impacting the future of care delivery and virtual care delivery, this is one chat you won’t want to miss!

#Healthin2Point00, Episode 208 | Cedar acquires Ooda & funding for Medically Home, Huma

Today Jess is bored with consistent $100m+ deals and yawns in the face of the Tiger! No matter– I explain what Cedar acquiring Ooda for $425m means, why $100m for Medically Home is a departure for Mayo but not Kaiser, and what the heck Huma is all about (OK, I don’t really know). Does Jess get more interested by the end? You’ll have to watch to find out!–Matthew Holt

THCB Gang Episode 54, Thursday May 13

Episode 54 of “The THCB Gang” was held on Thursday, May 13. Matthew Holt (@boltyboy) was joined by regulars: policy expert consultant/author Rosemarie Day (@Rosemarie_Day1); medical historian Mike Magee (@drmikemagee), THCB regular writer Kim Bellard (@kimbbellard) employer health expert Jennifer Benz (@jenbenz); and WTF Health host & Health IT girl Jessica DaMassa (@jessdamassa).

The topic ended up looking at the role of employers in dealing with inequality in health care, and whether the digitally enabled primary care navigation organizations could help. A great discussion!

Then video is below. If you’d rather listen, the audio is preserved as a weekly podcast available on our iTunes  & Spotify channels.

#Healthin2Point00, Episode 207 | Aetion, Halodoc, Vori, Heartbeat Health & Memora Health

Today on Health in 2 Point 00, the survey says digital health is optimistic! Find out more on the other side. On Episode 207, Jess asks me about Aetion getting $110 million bringing its total to $212 million working on real world evidence for pharma companies, and Indonesian telehealth company Halodoc gets $80 million. MSK startup Vori Health gets $45 million—can they compete with Hinge? Next, Heartbeat Health gets $20 million for cardiovascular health. Finally, Andreesen throws $10.5 million in a Series A to Memora Health which is a patient messaging system. Don’t forget to join us on Clubhouse tonight for more! —Matthew Holt

#Healthin2Point00, Episode 206 | Walmart buys MeMD, Science 37 SPACs out, Vim & Zoe

Today in #Healthin2Point00, Jessica is not impressed by my stock trading and it’s all Walmart’s fault (well, Amazon’s too)! Part of the reason for that is Walmart buying a no-name telehealth company–well it has a name but not one anyone knows. There’s a SPAC exit on the horizon for fast growing remote clinical trials company Science37, and funds for Vim which does scheduling (we think!), and Zoe which sells a diet so expensive you might actually stick to it!–Matthew Holt

#Healthin2Point00, Episode 205 | Groups, Collective Health, Oura Ring & Ciitizen buys Stella

Today on Health in 2 Point 00, it’s time for the silliness to end, and for Jess DaMassa and I to take digital health deals seriously. Groups gets $60 million from a bunch of famous investors. Oura, they of the tracking ring used by the NBA, gets $100m, and TPA substitute Collective Health gets a whopping $280m from a big Blues plan. And our favorite privacy maven Deven McGraw gets a mention as her company Ciitizen buys interoperability tech company Stella. Did we maintain our serious demeanor? You’ll have to watch to find out but you can probably guess the answer!Matthew Holt

#Healthin2Point00, Episode 204 | Vida, Headway, & Neuroelectrics, plus RCM acquires VisitPay

Today on Health in 2 Point 00, I am over the moon excited about Chelsea’s Champion’s League semi-final win. But on Episode 204, we have some big deals to cover too. First, Vida Health gets $110 million in a Series D bringing their total to $188 million. Next, R1 RCM acquires VisitPay for $300 million, integrating patient financial engagement into their revenue cycle management offerings. It’s Mental Health Awareness Month, and mental health startup Headway raises $70 million – do they have a chance in that crowded space? Finally, Neuroelectrics gets $17.5 million for their neurostimulation cap helping with epilepsy and depression. —Matthew Holt

Inside Vida Health’s $110M Series D & Big Push into Digital Mental Health

By JESSICA DaMASSA, WTF HEALTH

It’s another mega-round for a digital health chronic condition management startup, as Vida Health closes its $110M Series D – AND adds a pair of big-name insurers to their cap table. Vida’s Founder & CEO, Stephanie Tilenius, gets into the good news about the funding round, which was led by growth equity fund, General Atlantic, and brought managed care giant Centene (a Vida customer) and multinational insurer AXA into the mix.

Beyond the funding – and the extra “insurance side” endorsement it gives to the virtual chronic condition care space – what’s interesting about Vida now is how its “whole person” approach, which integrates physical health care and mental health care, is very much tilting to mental health these days.

While overall revenue has tripled since last year, Stephanie talks about how the 6000% year-over-year growth for her mental health services has played into that rise, and how the new funding will be used to further expand those offerings.

Does this mean we need to start naming Vida as a competitor to digital mental health companies like Ginger, Modern Health, and Talkspace? And, how does this impact their positioning among the field of other health tech chronic care co’s? For those who may have forgotten, Vida went out the gate with a platform that was designed to treat both the mental-and-physical aspects of chronic disease, while others like Omada and Livongo-now-Teladoc acquired-and-integrated behavioral health providers to augment their physical-first offerings and satisfy customer demands. Will it now prove easier for Vida to scale-up and scale-out, having been built for both “mind and body” from the very beginning? Stephanie’s got her opinion, big plans, and now a treasury to rival those key competitors across both fields of care. Tune in for all the details!

Registration

Forgotten Password?